

Infusion Readiness Checklist

Preparatory
checklist for
initiating TZIELD[®]
(teplizumab) in
your centre

This promotional material is created and funded by Sanofi for healthcare professionals who prescribe or plan to prescribe TZIELD in the UK.

▽ Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com

TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years and older with Stage 2 T1D.¹



TZIELD UK Prescribing Information can be accessed [here](#), or by scanning the QR code.

The purpose of this checklist



This checklist outlines key considerations for clinical teams who are responsible for delivering TZIELD infusions.



Fill in this Infusion Readiness Checklist to help you prepare your centre, staff, and eligible patients for TZIELD. Once you've completed it, keep a copy for your record to refer to in the future.

Hospital Details

Name:

Address:

Step 1 Form a Multidisciplinary Team

- ☐ Designate a Lead Clinician

Name:

- ☐ Create a Multidisciplinary Team and confirm 14-day availability

Lead Clinician:

Infusion Nurse:

Pharmacist:

Hospital Lab Lead:

Administrative Lead:

- ☐ Align the Multidisciplinary Team using this Infusion Readiness Checklist

Step 2 Prepare the Endocrinology Team

☐ Complete infusion training for the Endocrinology Team

- Infusion training must include management of adverse events and other important patient safety considerations

☐ Define available infusion options for the 14-day infusion period

- Clinical Research Facilities or Ambulatory Care Centres may be suitable for weekend infusions
- Consider patient/carer responsibilities and availability of clinicians to manage potential lymphopenia around Day 5¹

Weekday details:

Weekend details:

Home infusion details (if available):

☐ Create a contingency plan for missed doses

Outline plan:

Step 3 Prepare the Infusion Team

☐ Complete infusion training for the Infusion Team

☐ Allocate location for TZIELD reconstitution

- If not used immediately, diluted solutions must be stored at room temperature (15–30°C) and infusion completed within 4 hours of the start of preparation¹

Location:

☐ Designate rooms/bed space available for the infusions

Rooms/beds:

☐ Source all infusion equipment and/or necessary items:¹

- PVC infusion bags
- Syringes in various sizes
- 0.9% sodium chloride
- Infusion pump
- Catheter
- Pre-medication
- TZIELD vials
- Routine infusion supplies
- Resuscitation equipment/emergency management

Illustrative list. It is the HCP's responsibility to define the complete list of infusion equipment required.

☐ Designate location and individual responsible for monitoring patients for adverse reactions

Location:

Name:

☐ Establish risk management protocols for infusion reactions and escalation

Outline protocol:

☐ Collect patient emergency contact information

Step 4 Reduce patient wait times

- ☐ Add TZIELD to the EPR system with built-in dose calculation or validated BSA dosing calculator

- Please refer to the online TZIELD dosing calculator

- ☐ Outline procedure for ordering and storing TZIELD period

- If pharmacy does not operate 7-days a week, pre-dispensed doses and vials will need collecting and storing
 - Vials must be refrigerated at 2–8°C¹

Procedure:

- ☐ Outline pharmacy reconstitution wait times period

Wait times:

- ☐ Inform hospital laboratory of timescale required for test results (pre-infusion and ongoing monitoring)

Timescale:

- ☐ Outline a patient schedule that minimises wait times from pharmacy and hospital lab tests

Schedule:

- ☐ Plan practical solutions for patient transport and accommodation

- Discuss transport over the 14-day period with patient transport services and local charities

Outline plan:

Step 5 Create a seamless administrative experience

☐ Designate individual responsible for reviewing vaccination records

- Ensure all vaccinations are completed in sufficient time before treatment commences¹

Name:

☐ Designate individual responsible for ordering baseline lab tests

Name:

☐ Designate individual responsible for final patient eligibility validation

Name:

☐ Designate individual responsible for infusion scheduling

Name:

☐ Designate at-home infusion co-ordinator (if applicable and available)

Name:

Step 6 Prepare for monitoring post-treatment

☐ Plan how patients will be monitored after TZIELD treatment

- Inform patient's GP about treatment completion and follow-up requirements
- SNOMED code 1290118005

Outline plan:



Scan the QR code
to access the
TZIELD Website

BSA, body surface area; **EPR**, Electronic Prescribing Record; **PVC**, polyvinylchloride;
SmPC, Summary of Product Characteristics; **T1D**, Type 1 diabetes.

Reference: 1. TZIELD® (teplizumab) UK Summary of Product Characteristics.

© 2026 Sanofi. All rights reserved. MAT-XU-2600410 (v3.0) | September 2026